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Abstract
Background: The range of combination antiretroviral therapy (cART) regimens available in many middle-income
countries differs from those suggested in international HIV treatment guidelines. We compared first-line cART
regimens, timing of initiation and treatment outcomes in a middle income setting (HIV Centre, Belgrade,
Serbia - HCB) with a high-income country (Royal Free London Hospital, UK - RFH).
Methods: All antiretroviral-naïve HIV-positive individuals from HCB and RFH starting cART between 2003 and
2012 were included. 12-month viral load and CD4 count responses were compared, considering the first available
measurement 12-24 months post-cART. The percentage that had made an antiretroviral switch for any reason,
or for toxicity and the percentage that had died by 36 months (the latest time at which sufficient numbers remained
under follow-up) were investigated using standard survival methods.
Results: 361/597 (61 %) of individuals initiating cART at HCB had a prior AIDS diagnosis, compared to 337/1763
(19 %) at RFH. Median pre-ART CD4 counts were 177 and 238 cells/mm3 respectively (p < 0.0001). The most
frequently prescribed antiretrovirals were zidovudine with lamivudine (149; 25 %) and efavirenz [329, 55 %] at HCB
and emtricitabine with tenofovir (899; 51 %) and efavirenz [681, 39 %] at RFH. At HCB, a median of 2 CD4 count
measurements in the first year of cART were taken, compared to 5 at RFH (p < 0.0001). Median (IQR) CD4 cell increase
after 12 months was +211 (+86, +359) and +212 (+105, +318) respectively. 287 (48 %) individuals from HCB and
1452 (82 %) from RFH had an available viral load measurement, of which 271 (94 %) and 1280 (88 %) were <400
copies/mL (p < 0.0001). After 36 months, comparable percentages had made at least one antiretroviral switch
(77 % HCB vs. 78 % RFH; p = 0.23). However, switches for toxicity/patient choice were more common at RFH. After
12 and 36 months of cART 3 % and 8 % of individuals died at HCB, versus 2 % and 4 % at RFH (p < 0.0001).
Conclusion: In middle-income countries, cART is usually started at an advanced stage of HIV disease, resulting in
higher mortality rates than in high income countries, supporting improved testing campaigns for early detection of
HIV infection and early introduction of newer cART regimens.
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Background
Since the introduction of combination antiretroviral
treatment (cART), morbidity and mortality in those
living with human immunodeficiency virus (HIV) has
dramatically decreased [1, 2]. Treatment has been par-
ticularly effective in high-income countries, where the
full spectrum of antiretroviral drugs (ARVs) are widely
available, along with early access to experimental drugs
[2, 3]. However, HIV therapy options in low-middle and
middle income countries remain limited. In contrast to
high income settings, the choice of cART regimen pre-
dominantly depends on which antiretroviral drugs are
available, regardless of those recommended in treatment
guidelines [4, 5].
The Strategic Timing of Antiretroviral Treatment
(START) study showed that immediate initiation of
cART with a CD4+ T-cell count >500 cells/mm3 led to
lower rates of serious AIDS-related and non-AIDS-
related illnesses and death compared to deferring cART
until the CD4 count reached 350 cells/mm3 [5]. Thus,
timely HIV diagnosis and introduction of cART is of
great importance. However, in reality HIV-testing rates
in high income countries are higher compared to low,
low-middle and middle income settings. Consequently,
higher numbers of individuals with HIV are diagnosed
late and start cART with more advanced disease in these
settings, with resulting higher mortality rates [3–5].
The objective of this study was to compare the ARVs
used in first line therapy, timing of cART initiation,
frequency of monitoring, frequency of cARV switches
and treatment outcomes between a middle income




This study included all previously antiretroviral-naive in-
dividuals with HIV initiating cART from January 1st
2003 until 1st June 2012. Participants from Serbia, a
middle income country, were attendees at the HIV/AIDS
Center of the University Hospital for Infectious and
Tropical Diseases in Belgrade (HCB). This is the largest
center in Serbia, caring for over 90 % of cART-treated
individuals in the country. A retrospective notes review
of suitable patients was performed for the purpose of
the study. Patients from the United Kingdom, a high in-
come country, were attendees at the Ian Charleson Day
Centre, Royal Free London Hospital (RFH), whose pa-
tient population has a demographic profile that is
broadly representative of the UK HIV epidemic. Details
of this cohort are given elsewhere [6]. The Royal Free
HIV Cohort has approval to analyse anonymous rou-
tinely collected data from the Royal Free Hospital and
Medical School Research Ethics Committee via
Chairman's action. Data collection at HCB was approved
by the Clinical Centre of Serbia Ethics Committee, ap-
proval number 29/XI-5. At the time of analysis, follow-
up was available until 1st June 2012.
Laboratory methods
CD4+ T-cells were quantified by flow cytometry in both
centres. HIV-1 RNA plasma viral load (pVL) was mea-
sured by quantitative reverse transcriptase polymerase
chain reaction (Ultrasensitive assay version 1.5, Roche
Molecular Systems, Branchburg, NJ, USA), with a lower
limit of detection of 50 copies/mL. At the HCB, pre-
cART CD4 counts were available for most patients,
whereas baseline pVL and genotypic resistance testing
are not performed. At the RFH, pre-cART CD4 counts,
pVL and resistance tests are routinely performed for all
patients.
ARV availability
In Serbia, the following ARVs were available during the
study period: a) nucleoside reverse transcriptase inhibi-
tors (NRTIs): zidovudine, lamivudine, didanosine, stavu-
dine, abacavir, and the fixed dose combinations of
zidovudine with lamivudine and abacavir with lamivu-
dine; b) non-nucleoside reverse transcriptase inhibitors
(NNRTIs): nevirapine and efavirenz; c) protease inhibi-
tors (PIs): saquinavir, nelfinavir, indinavir, fosamprenavir,
lopinavir/ritonavir, and low-dose ritonavir. Nelfinavir
and indinavir were withdrawn in 2008. Enfuvirtide was
registered in 2007 solely for highly treatment experi-
enced individuals with previous treatment failure. Inte-
grase inhibitors and CCR5 receptor antagonists were not
available. Ritonavir-boosted darunavir was available as a
compassionate treatment, and as such was used in a very
few patients. During the study period there were no spe-
cific National HIV treatment guidelines available, but
doctors followed the European AIDS Clinical Society
(EACS) guidelines wherever possible.
All antiretrovirals available in Serbia were also avail-
able in the United Kingdom. In addition, the following
antiretrovirals were available: a) NRTIs: tenofovir, emtri-
citabine, and the fixed dose combination tenofovir with
emtricitabine; b) NNRTIs: etravirine; c) PIs: atazanavir,
darunavir and indinavir; d) integrase inhibitors: raltegra-
vir; e) fusion and entry inhibitors: enfuvirtide and mara-
viroc. In addition, other experimental drugs could be
used as part of clinical trials. During the study period,
clinicians followed current British HIV Association
(BHIVA) guidelines [7].
Statistics
Baseline was defined as the date of starting cART. We
described the participant characteristics at baseline, fo-
cusing on the specific NRTI backbone and ‘third’ drug
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used in the initial regimen. Comparisons between HCB
and RFH were made using chi-squared tests, Fisher’s
exact tests and Mann-Whitney U tests, as appropriate.
Loss-to-follow-up was defined as not engaging in care
for a period of longer than 12 months, and standard
Kaplan-Meier methods were used to estimate the per-
centage to follow-up after 12 months.
The frequency of viral load and CD4 count monitoring
in the first 12 months of ART were compared between
the two settings. Immunological and virological response
to cART was calculated after 12 months of ART, by con-
sidering the first CD4 count and pVL measurement re-
corded in the time period 12 to 24 months after start of
ART. This definition was chosen as it is an analysis ap-
proach that is relatively insensitive to differences in fre-
quency of monitoring between groups. A pVL cut-off of
400 copies/ml was considered so that low-level ‘blips’
were not considered as lack of virological response.
Clinician-defined reasons for switch were categorized
into the following groups: virological failure, toxicity,
dose reduction and/or ART simplification, patient
choice, other reasons and not recorded. Switches for pa-
tient choice were only made at RFH. An additional rea-
son for switch, only applicable in Serbia, was lack of
drug supply, assigned when a particular antiretroviral
was unavailable and so patients were prescribed an
alternative (i.e. available) drug(s). Here, a drug from the
combination would be replaced with a similar one (e.g.
tenofovir with zidovudine or didanosine; lopinavir/r with
fos-amprenavir; efavirenz with nevirapine). Switches
were always made in accordance with antiretroviral his-
tory, previous toxicity, and results of previous genotypic
HIV resistance tests if available.
Time to first switch of any drug in the cART regimen
for any reason and for toxicity reasons were investigated
using Kaplan-Meier methods, and the percentage that
had made a switchby 36 months (a time point at which
sufficient numbers remained under follow-up to allow
accurate estimation) was reported. Individuals were
followed from baseline until the date of the first change
made to the cART regimen for any reason (or until the
date of a switch made for toxicity reasons, ignoring any
prior switches made for other reasons), or date of the
last available pVL measurement, whichever occurred
first. Two additional analyses were performed. Firstly, a
time to first switch for any reason was re-performed for
those from HCB, excluding “lack of drug supply” as a
reason for stopping. Secondly, although “patient choice”
was included as a ‘toxicity’ in primary analysis (as this
reason represents tailoring regimens to an individual’s
specific needs), a secondary analysis excluding “patient
choice” as a “toxicity” discontinuation was also per-
formed. Time to death was similarly investigated using
Kaplan-Meier methods. All p-values of less than 0.05
were considered to demonstrate statistical significance.
Analyses were performed using SAS Version 9.3 (SAS
Institute Inc, Cary, NC).
Results
Baseline characteristics
There were 597 individuals from the HCB and 1763 in-
dividuals from the RFH who started cART during the
study period, with a median (IQR) follow-up of 1.3 (0.4,
2.3) years and 3.4 (1.4, 5.6) years respectively. At the
time of treatment initiation, those from the HCB had
more advanced disease, with 361 (61 %) having a prior
AIDS diagnosis (28 tuberculosis, 26 oesophagael can-
didiasis, 25 wasting syndrome) compared to 337
(19 %; 110 tuberculosis, 64 PCP, 33 Kaposi’s Sarcoma,
26 oesophageal candidiasis) at the RFH (Table 1). In
addition, the median (IQR) pre-cART CD4+ T-cell
counts was 177 (85, 298) cells/mm3 at HCB com-
pared to 238 (123, 339) cells/mm3 at RFH.
Over calendar time, increases in the median pre-cART
CD4+ T-cell counts were observed at both centres. At
HCB, the median pre-ART CD4+ T-cell count was 110
cells/mm3 amongst those starting cART in 2003, in-
creasing to a median of 197 cells/mm3 in 2007 and 298
cells/mm3 in 2012. Equivalent figures for RFH were 208
cells/mm3 in 2003, 225 cells/mm3 in 2007 and 319 cells/
mm3 in 2012.
Components of cART regimen
There were significant differences in the choice of first-
line NRTI backbones at the two centres (p < 0.0001 chi-
squared test, Fig. 1a and 1b). At the HCB, the most fre-
quently prescribed NRTI backbone combinations were
zidovudine with lamivudine (149; 25 %), didanosine with
another NRTI (149; 25 %) and abacavir with lamivudine
in (143; 24 %). In contrast, at the RFH the most fre-
quently prescribed NRTI backbones were emtricitabine
with tenofovir (899; 51 %), zidovudine and lamivudine
(153; 20 %) and abacavir with lamivudine (141; 8 %). At
the HCB, NNRTI-based regimens were prescribed for
71 % (423; 55 % [329] efavirenz, 15 % [92] nevirapine
and 0.2 % [1] other) versus 45 % at the RFH (793; 39 %
[681] efavirenz, 6 % [109] nevirapine and 0.2 % [4] other)
(Figs. 1c and 1d; p < 0.0001; chi-squared test).
Response after 12 months of cART
Twelve months after the start of ART, 21.4 % (95 % CI
17.9 %, 24.9 %) at HCB and 7.4 % (6.4 %, 8.6 %) at RFH
had been lost-to-follow-up. There were significant differ-
ences in the frequency of CD4 count and pVL monitor-
ing between the two centres. At the HCB, the median
(inter-quartile range, IQR) number of CD4+ T-cell
counts and HIV-1 RNA pVL measurements in the first
year of cART was 2 (1, 2) and 1 (0, 2), respectively;
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compared to 5 (3, 7; p < 0.0001) and 5 (4, 7; p < 0.0001)
at the RFH, respectively.
Three hundred and twenty four (54 %) individuals at
HCB had a 12-month CD4 count measurement avail-
able, measured at median of 15 months post-cART
(75 % [243] were within 12 to 18 months). The median
(IQR) was 341 (226, 487) cells/mm3, representing a
change of +211 (+86, +359) cells/mm3 compared to pre-
cART values. A substantially higher proportion (1291;
73 %) from RFH had an available CD4+ T-cell counts
measurement, taken a median of 14 months after the
start of cART (93 % [1206] were within 12 to 18 months).
The median value was considerably higher than at HCB,
with a value of 437 (296, 580) cells/mm3. However, this
corresponded to a comparable increase of +212
(+105, +318) cells/mm3 compared to pre-cART values.
Of the 597 starting ART at HCB, 287 (48 %) had a VL
measurement available after 12 months cART; 113
(19 %) were lost to follow-up prior to this time; 117
(20 %) did not have sufficient follow-up (i.e. started ART
less than one year before the study close date), and the
remaining 80 (13 %) were under follow-up but without a
VL at this time. Of the 1763 starting cART at RFH, 1452
(82 %) had an available VL measurement after
12 months; 123 (7 %) were lost to follow-up, 43 (2 %)
did not have sufficient follow-up, and 145 (8 %) were
under follow-up but without a VL. Of those with a
measurement, 271 (94 %) at the HCB had pVL < 400
copies/mL, compared to 1280 (88 %) at the RFH. If one
assumes that those lost-to-follow-up had pVL > 400 cop-
ies/ml, then these percentages become 68 % (271/400) at
HCB and 81 % (1280/1575) at RFH.
At the end of follow-up (i.e. the last available meas-
urement, the percentage that did not achieve a CD4
count >500 cells/mm3 despite achieving a virological
response to cART at the HCB was 50 %. A similar
Table 1 Patients characteristics at commencement of antiretroviral therapy in the HIV Centre Belgrade (HCB) and Royal Free
Hospital (RFH) London
HCB RFH P-value
Number 597 (100 %) 1763 (100 %)
Gender Male 478 (80 %) 1234 (70 %) <0.0001
Female 119 (20 %) 529 (30 %)
Age Median (IQR) 38 (32-44) 36 (32-43) 0.05
Ethnicity White 597 (100 %) 892 (51 %) <0.0001
Black African 0 (0 %) 530 (30 %)
Other 0 (0 %) 341 (19 %)
Risk for HIV Acquisition Sex between men 218 (37 %) 850 (48 %) <0.0001
Heterosexual 155 (26 %) 839 (48 %)
Injecting Drug Use 90 (15 %) 49 (3 %)
Other 134 (22 %) 25 (1 %)
Calendar year 2003-2005 268 (45 %) 682 (39 %)
2006-2008 126 (21 %) 648 (37 %)
2009-2012 203 (34 %) 433 (25 %)
Previous AIDS Yes 361 (61 %) 337 (19 %) <0.0001
CD4+ T-cells count (cells/mm3) Median (IQR) 177 (85, 298) 238 (123, 339) <0.0001
(N = 575)* (N = 1519)**
pVL (log10 copies/mL) Median (IQR) -
+ 4.9 (4.3, 5.4)
(N = 1466)***
-
Previous TB diagnosis Yes 28 (5 %) 127 (7 %) 0.03
HCV Ab status Positive 131 (22 %) 88 (5 %) <0.0001
Negative 466 (78 %) 1005 (57 %)
Unknown 0 (0 %) 688 (39 %)
HBV sAg status Positive 78 (13 %) 53 (3 %) <0.0001
Negative 56 (87 %) 1005 (57 %)
Unknown 0 (0 %) 705 (40 %)
IQR = inter quartile range; TB = tuberculosis; pVL = plasma HIV RNA viral load; HCV Ab = Hepatitis C virus antibody; HBV sAg = hepatitis B virus surface antigen;
*available for 575 patients, **available for 1519 patients ***available for 1466 patients; + pre-cART pVL measurements not performed at HCB
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discordant response to cART occurred in 36 % pa-
tients treated at the RFH.
First line ARV changes
Over follow-up, 338 (56.6 %) individuals at HCB and
1372 (77.8 %) individuals at RFH made at least one
change to their cART regimen (Fig. 2a). At 36 months,
the percentage that had made at least one antiretroviral
switch to their cART regimen was virtually identical at
the two centers (77 %; 95 % CI 72 %, 82 % at the HCB
vs. 78 %; 76 %, 81 % at the RFH; p = 0.23). When exclud-
ing “lack of drug supply” as a reason for switching at
HCB, this centre had considerably lower switching rates
compared to RFH (p < 0.0001).
Although overall rates of switching between centers
were similar, the reasons given for switching were very
different. Considering the 338 first ARV switches at
HCB, 109 (32 %) were for lack of drug supply, 58 (17 %)
for toxicity [31 peripheral neuropathy, 21 pancreatitis, 6
lactic acidosis], 19 (6 %) for virological failure, 5 (1 %)
for dose reduction/ARV simplification and 147 (43 %)
for other reasons. In contrast, amongst the 1372 first
switches made at RFH, 417 (30 %) were for toxicity [98
CNS disorder, 70 diarrhoea, 39 rash, 33 lipodystophy, 31
anaemia, 30 renal problem, 28 nausea/vomiting, 18 lipid
abnormality, 18 deranged liver function tests, 10 abdom-
inal pain, 10 peripheral neuropathy, 32 other known],
170 (12.3 %) for patient choice, 91 (7 %) for virological
failure, 326 (24 %) for dose reduction/ARV simplifica-
tion, and 368 (27 %) for other reasons
As a result, switches made for toxicity and patient
choice reasons were considerably more common at the
RFH (46 % by 36 months; 95 % CI 43 %, 49 %) than at
the HCB (37 %; 31 %, 43 %; p <0.0001; Fig. 2b). When
excluding patient choice (which was a reason for stop-
ping for RFH only), the percentage making switches
were more similar (Fig. 2b).
Death
By the end of the study period, 31 (5.2 %) deaths had oc-
curred at the HCB and 72 (4.1 %) at the RFH. Mortality
at the HCB was significantly higher than at the RFH
(p < 0.0001; log rank test). After 12, 24 and 36 months
of commencing cART 3 %, 5 % and 8 % of patients
Fig. 1 Antiretrovirals included in first-line cART regimen: HIV Centre Belgrade, Serbia and Royal Free Hospital, UK. Antiretrovirals included in first
line cART at the HIV Centre Belgrade, Serbia (n = 597; a and c) and at the Royal Free Hospital, London, UK (n = 1763; b and d). Choice divided
according to nucleoside reverse transcriptase inhibitor (NRTI) backbone prescribed (a and b) and according to the ‘third’ drug (c and d) prescribed.
AZT – zidovudine, 3TC – lamivudine, ABC – abacavir, FTC – emtricitabine, TDF – tenofovir, ddI – didanosine, d4T – stavudine, NRTI - non-nucleoside
reverse transcriptase inhibitor, NNRTI - non-nucleoside reverse transcriptase inhibitor, LPV/r – lopinavir/ritonavir, PI/r – protease inhibitor boosted with
ritonavir, cART = combination antiretroviral therapy
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had died at the HCB respectively, compared to 2 %,
3 % and 4 % at the RFH (Fig. 3). In order to exclude
the effects of late diagnosis on these estimates, this
analysis was re-performed restricted to those that
started cART in a more timely manner with a CD4
count >200 cells/mm3 (n = 249 at HCB and n = 912 at
RFH), although this is no longer a representative sam-
ple of the complete populations. Differences between
the two centres were attenuated although still statisti-
cally significant (2.0 % at HCB vs 1.7 % at RFH had
died by 36 months; p = 0.006 log-rank test).
Discussion
Serbia is a middle income, non-European Union country
[8], with a relatively low prevalence rate of HIV infection
(less than 0.2 %) [9, 10]. Despite this, most HIV-positive
individuals are from vulnerable and/or marginalized
populations, such as intravenous drug users (IVDUs),
commercial sex workers and men who have sex with
men [11, 12]. Combination antiretroviral therapy in
Serbia is limited and the ability to provide treatment de-
pends on availability of antiretroviral drugs and supply,
a b
Fig. 2 Time to switching an antiretroviral: HIV Centre Belgrade, Serbia and Royal Free Hospital, UK. Kaplan-Meier plot of time from starting cART
to the first antiretroviral treatment switch (a) for any reason or (b) due to toxicity or patient choice. Comparison of HIV Centre Belgrade, Serbia
and Royal Free Hospital, London, UK. P-value obtained from log rank test
Fig. 3 Time from starting cART to death: HIV Centre Belgrade, Serbia
and Royal Free Hospital, UK. Kaplan-Meier plot of time from starting
cART to death. Comparison of HIV Centre Belgrade, Serbia and Royal
Free Hospital, London, UK. P-value obtained from log rank test
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regardless of current international treatment guidelines.
In contrast, the UK, a high-income country and member
of the European Union, has a wide range of all registered
ARVs together with new experimental drugs. Costs of
ARVs are fully covered by National Health Insurance in
both cohorts and are free at the point of access [12, 13].
During the study period some cART regimens, aban-
doned in UK due to increased drug toxicity and
decreased viral efficacy, were and are still used in
resource-limited settings, such as Serbia [14] as demon-
strated in this study.
Most patients from the Serbian cohort had a prior
AIDS diagnosis at cART initiation and mean baseline
CD4+ T-cell counts below 200 cells/mm3. In contrast, a
lower percentage of individuals from the RFH cohort
had an AIDS diagnosis when commencing cART. Un-
fortunately, information on the exact date of AIDS
diagnosis was not available at both centres, but the
policy at both was to start cART as soon as practical
after diagnosis, in line with treatment guidelines. Our
data are consistent with previous studies, strongly
suggesting that, in low-middle and middle income
countries, cART is usually introduced at an advanced
stage of HIV disease, as a direct consequence of low
testing rates [14]. In 2006, UNAIDS reported that
Serbia had one of the lowest HIV testing rates in
Europe, resulting in high percentage of individuals be-
ing diagnosed at a late stage of the disease [15]. The
Global Fund to fight HIV, tuberculosis and malaria
has supported Serbia to undertake National programs
to fight HIV/AIDS in order to improve quality of
provided health care services and in order to establish
conditions for establishing early diagnosis of HIV
[16]. Regardless of this, the number of late presenters
still remains an issue of concern.
Concerning the first line cART options, significant dif-
ferences were observed, especially when considering the
NRTI component of the regimen. In Serbia, the most
frequently prescribed NRTI was zidovudine in combin-
ation with lamivudine, followed by didanosine combined
with other NRTIs, in comparison to emtricitabine with
tenofovir at RFH. Indeed, didanosine was not used at all
in study participants from the RFH, due to its exclusion
as a recommended first-line drug in national guidelines,
and concerns regarding increased toxicity and virological
failure. In contrast, didanosine was routinely prescribed
in the first regimen at HCB, and some patients remained
on the drug throughout follow-up. Use of an NNRTI as
the "third" drug of the regimen was more common at
the HCB than at the RFH, due to a more limited number
of drugs being available in Serbia. Relatively newer
drugs, such as tenofovir, emtricitabine, darunavir, tipra-
navir, etravirine, raltegravir and maraviroc were not
available during the study period.
The frequency of CD4+ T-cells count and HIV-1 RNA
pVL monitoring varied significantly between those two
cohorts. At the HCB, monitoring was below inter-
national recommendations for assessment of HIV-
positive individuals [17, 18]. The ART-LINC study
group, conducted a collaborative analysis in 27 treat-
ment centers in a low and in a middle income countries
from Asia, Latin America and sub-Saharian Africa, and
found that the frequency of CD4+ T-cell counts testing
varied by site, but generally was approximately two tests
per year [19]. The EuroSIDA group conducted a sub-
study in a resource-limited settings, which revealed
more frequent monitoring of CD4+ T-cell counts than
of viral loads, which potentially leads to the greater
number of virological failures during cART use [20].
These data are consistent with our findings.
As expected, in our study, increases in CD4 count
after one year of cART at both centres was substantial
and statistically significant. Furthermore, extremely high
rates of virological suppression were seen at both cen-
tres. These results are compatible with previously pub-
lished results [17, 18, 21, 22]. Significant improvement
in CD4 counts and very high percentages with undetect-
able in response to cART in the middle income settings,
such as Serbia, are still being achieved even though older
drugs were used in cART regimens. There are few clin-
ical trials demonstrating the clinical superiority of one
regimen over another, instead, licensing bodies rely on
CD4+ T-cell counts and HIV-1 RNA plasma viral load
as surrogate markers, and that changes in these will ul-
timately translate into clinical benefits [23, 24]. A num-
ber of studies from middle income countries suggest
significant issues with immune reconstitution in associ-
ation with low baseline CD4+ T-cell counts, as long pe-
riods of time are needed until counts recover to the
normal range of >500 cells/mm3 [5–25]. These data are
consistent with our study.
After three years of first line cART, there was almost
the same frequency of initial ART switch in both centers.
However, a lack or interruption of drug supply was the
most common reason for treatment change at the HCB,
which was never a consideration at the RFH. In a previ-
ously reported analysis of the ICONA data [26], the
overall risk of discontinuation of first-line cART was
36 % with 21 % due to intolerance/toxicity. In their up-
dated analysis of treatment discontinuation in HIV-1-
infected individuals starting their first-line HAART after
2008 they reported the main reason for stopping was
simplification, reflecting the recent changes in recom-
mendations aimed to minimize drug toxicity, enhance
adherence and improve quality of life [27]. Our study
shows that switches for reasons that are not always a
“necessity” were much more frequent at the RFH, and
reflected tailoring regimens to an individual’s needs
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including making changes for patient choice. In contrast,
at the HCB, such switches were less common due to
limited access to alternative regimens. This highlights
the fact that individuals from middle-income settings are
considerably more likely to need to make switches to
their ART regimen and must make these changes more
quickly than those from a high income setting, which
could potentially be disruptive for the treated patient.
Finally, mortality rates were significantly higher in the
HCB than in the RFH cohort, over the first three years
after starting cART. Those patients who initiated cART
at advanced stage of the disease, which is more frequent
in Serbia than in UK, are at increased risk of dying, a
finding seen in other similar studies [4, 20, 28]. Our data
acts as vital information for health care authorities in
the Republic of Serbia as evidence for the need for sup-
port of and improvements in testing campaigns. This
could lead earlier detection of HIV infection and intro-
duction of cART when individuals are less immune-
compromised, both of which have well known clinical
benefits. In addition, it highlights the issue of interrup-
tions in the supply chain for antiretrovirals that was
present throughout the study period, and which could
be improved in the near future. Finally, registration and
availability of newer drugs and those still not available at
the Republic of Serbia, especially those from the inte-
grase inhibitor class could improve tolerability and re-
duce the need for drug switching.
Conclusion
In a middle income country such as Serbia, as a conse-
quence of low HIV-testing rates, antiretroviral treatment
is still introduced at an advanced stage of disease. This
results in higher mortality rates than in high income
countries, such as the UK. Switches of regimen from
first line cART are more often due to the lack of drug
supplies in such a resource limited setting, while in the
high income setting switches are more frequently made
in order to tailor regimens to individual patient needs.
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